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Objective: To realize a retrospective study of the characterization, results, and effectiveness 
of directly observed therapy, short course (DOTS) in the regional health area of Santiago de 
Compostela (population 453 068) between 1996 and 2006.
Design: Tuberculosis (TB) patient cases involved in DOTS treatment were reviewed. The 
studied variables included: age, sex, type of TB, TB location, microbiological studies, chest 
radiology, pattern and treatment duration, final status of case, and TB recurrence.
Results: There were 2456 diagnosed TB cases in the time period studied and 259 received 
DOTS. The reasons for inclusion in this treatment strategy were social dystocia in 33.2% of 
cases, retreatment in 30.8% of cases, alcoholism in 29.3% of cases, drug use in 17.4% of cases, 
HIV coinfection in 11.6% of cases, multidrug-resistant strains of TB (MDR-TB) in 3.1%, 
and being an immigrant in 1.9% of cases. Primary TB represented 3.5% of the instances and 
pulmonary TB represented 87.6%. Bacteriological confirmation was performed in 76.8% of this 
population. Cavitated forms in chest radiology were shown in 46.7% of patients. Standard treat-
ment guidelines were used in 71.4% of patients. Treatment adherence was achieved in 96.1% 
of the cases and 86.9% cases had a successful final status. Recurrence of TB was 1.5%.
Conclusion: Although it is not possible to determine the exact influence of the DOTS strategy, 
its introduction under the conditions of the Galician Program for Prevention and Control of 
Tuberculosis (GPPCT)5 has worked to improve the control of tuberculosis in our health area.
Keywords: tuberculosis, DOTS, selection criteria, drugs, recurrence
Introduction
Tuberculosis (TB) is an infectious disease for which effective treatment has been avail-
able for more than 50 years. However, TB has neither been eradicated nor controlled 
globally and it remains an important public health problem.
The estimated number of cases world wide in 2006 was 9.2 million (139 cases/ 
100,000 people).1 The factors that have contributed to this situation are poverty, spread 
through migration, lack of disease control, the new epidemic of HIV/AIDS, and the 
emergence of multidrug-resistant strains of TB (MDR-TB).2,3
The current incidence of TB in Spain is not known. In 2007, a working group of experts 
on TB was created as a result of a proposal by the Spanish Government Health and Consump-
tion Ministry and a “Plan for prevention and control of TB in Spain” was established.4 In 
1995, the Galician Program for Prevention and Control of Tuberculosis (GPPCT)5 published 
epidemiological data on TB incidence in Galicia, in the northwest region of Spain. In 1996, 
the incidence of TB in Galicia was found to be about 72.3 cases/100,000 people and in 2006 
about 37.7 cases/100,000 people, which indicates a 7% annual decrease.6Risk Management and Healthcare Policy 2010:3 submit your manuscript | www.dovepress.com
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Perhaps the most important action to accelerate the reduc-
tion in TB and to control it is to establish early treatment of all 
patients and to guarantee proper observance of the established 
treatment guidelines. It has been estimated that between 20% 
and 50% of patients do not take their treatment properly or 
do not complete the whole prescribed regimen. Both these 
situations may lead to therapeutic failure and the emergence 
of secondary resistance.7
A new strategy to control this disease called Stop TB was 
launched by the World Health Organization (WHO) in 2006.1 
The core of this strategy was directly observed therapy, short 
course (DOTS), proposed by the WHO in 1994.8 The strategy 
involves observing patients taking their medications to ensure 
they are consumed in the right combination and for the cor-
rect duration.9 The first component of the Stop TB strategy, 
DOTS expansion and enhancement, is the cornerstone. The 
basic components of the DOTS strategy are: political com-
mitment to increased and sustained financing; case detection 
through quality-assured bacteriology; standardized treatment 
with supervision and patient support; systems for effective 
drug supply, management, monitoring and evaluation; and 
impact measurement.8
The GPPCT is trying to implement this DOTS method 
gradually, at least in those patients in whom a higher likeli-
hood of withdrawal is expected.10
This paper reports a retrospective study of the charac-
terization, results, and effectiveness of DOTS in relation to 
TB in the health area of Santiago de Compostela between 
1996 and 2006.
Material and methods
Data were obtained from the following sources at the 
Santiago de Compostela University Hospital Complex: 1) 
the TB unit (UTB) database, 2) patient clinical histories, 
3) Microbiology Service registrations, and 4) Hospital 
Pharmacy Service information obtained from the unit dose 
dispensing program.
Informed patient consent and ethical approval were not 
required for this retrospective study.
The TB patients included in the study were those who 
received DOTS from January 1996 to December 2006. All 
patients belonged to the Santiago de Compostela health area 
(population 453,068). DOTS was established by the UTB, 
located in the Preventive Medicine Department of the Santiago 
de Compostela University Hospital. The criteria for patients 
to be included in DOTS were: retreatment cases (ie, treatment 
after default or relapse and chronic cases), evidence of HIV 
infection, drug use, alcoholism, psychiatric illness, social 
dystocia, if they were immigrants, and/or exhibited MDR-TB. 
Patients were excluded from the study if they represented 
relapsed cases of TB diagnosed more than 15 years ago.
In order to analyze DOTS administration, two points need 
to be considered: the wide population dispersion in the health 
area analyzed and the resulting inability to centralize treatment 
administration. That is why, for this study, the decision on 
the location and selection of appropriate people to administer 
DOTS was individualized and conducted on the basis of a social 
and clinical report of the patient, with their agreement.
The variables included in the study were: age, sex, type of 
TB, TB location, microbiological studies, chest radiology, pat-
tern and treatment duration, and case final status. TB type was 
classified according to internationally accepted recommenda-
tions.11 TB location could be primary complex, pulmonary, or 
extrapulmonary (eg, pleural, miliar, meningeal, lymph nodes).
Microbiological studies were performed in the Micro-
biology Department of Santiago de Compostela University 
  Hospital, which has WHO recognition as a TB reference 
center in Galicia.12 The studies conducted were: stains 
acid-fast bacilli (AFB), culture in liquid medium (using 
BACTEC™ MGIT™ 960 system; BD, Franklin Lakes, 
NJ), drug susceptibility testing (DST) to the first-line 
drugs (isoniazid [H], rifampicin [R], ethambutol [E], 
pyrazinamide [Z], streptomycin [S]) and to second-line drugs 
(levofloxacine, capreomycin, prothionamide, amikacin, PAS, 
cycloserine, ciprofloxacin, ofloxacin).
Case final status was defined following the GPPCT pro-
tocol and included the following options: bacteriogical cure, 
completed treatment, default, death from TB, death from 
other causes, or transferred out.5 Treatment adherence has to 
be ensured in all patients, which includes those patients who 
died or were transferred to another health area.
TB recurrence in DOTS cases was defined as rediagnosis of 
TB in previously treated patients who had undergone DOTS.
Data for this study was managed by MS Excel™ for 
  Windows® XP, and analyzed with the statistical package SPSS 
v12 for Windows®. Associations between variables were 
tested using the Pearson chi-square. All tests were two-sided 
and P values , 0.05 indicated significant differences.
Results
There were 2456 cases of TB diagnosed in the Santiago de 
Compostela health area between 1996 and 2006. Among 
these, 253 patients (10.3%) received 259 DOTS treatments. 
There were 58 women (22.9%) and 195 men (77.0%), with 
an average age of 39.9 years (range 0–83).
The distribution of total cases under DOTS by type of 
TB, over two time periods (1996–2000 and 2001–2006), is 
shown in Table 1.Risk Management and Healthcare Policy 2010:3 submit your manuscript | www.dovepress.com
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Social dystocia and psychiatric illness met the inclusion 
criteria in 86 cases (33.2%), alcoholism in 76 (29.3%), drug 
abuse in 45 (17.4%), HIV-TB coinfection in 30 (11.6%), 
MDR-TB in 8 (3.1%), immigration in 5 (1.9%), and 80 
(30.8%) were retreatment cases. Fifty-six patients (21.6%) 
presented with more than one criterion for inclusion.
With regards to TB type, 179 (69.1%) of these patients were 
newly diagnosed cases and 80 (30.8%) were being retreated 
for TB. Among the latter, 31 (38.7%) were classified as treat-
ments after default, 45 (56.2%) were relapse cases and 4 (5%) 
had chronic illness. Of the 179 patients with newly diagnosed 
TB, 16 (9%) met more than one criterion to be included in the 
DOTS program, while there were 40 patients in this situation 
among the 80 (49.4%) retreatment cases (P , 0.01).
The distribution of TB cases according to location 
and microbiology was as follows: 1) there were 9 (3.5%) 
primary complex TB cases, with only 1 case confirmed 
bacteriologically. Microbiological study was not performed 
in 8 cases; 2) there were 227 (87.6%) pulmonary TB cases, 
170 (74.9%) of which had a positive AFB stain. Bacterial 
presence because of positive culture growth was confirmed 
in 191 (84.1%) patients. Bacteria were not isolated in 9 cases 
with positive AFB. Microbiological studies were negative in 
28 (12.3%) cases; 3) there were 23 (8.8%) extrapulmonary 
TB cases, 5 (21.7%) of which were AFB positive, 7 (30.4%) 
had bacteriological confirmation, 4 (17.4%) had negative 
bacteriology, and no microbiological studies were carried 
out in 12 (52.2%) patients; 4) bacteriological confirmation 
was performed in 199 (76.8%) DOTS cases and of the 227 
patients with pulmonary TB, 106 (46.7%) presented cavi-
tated forms in their chest radiology while 114 (50.2%) had 
noncavitated images.
The physical locations where DOTS administration was 
conducted are shown in Table 2. Table 3 shows the pattern 
of and treatment regimens for this therapy, classified as: 
standard and internationally accepted patterns, extended 
regimens, and other guidelines. The latter include not only 
the treatment of resistant and MDR cases, but changes in the 
therapy because of intolerance and/or drug toxicity.
Treatment adherence was achieved in 249 (96.1%) cases. 
The final case status is described in Table 4. Of those patients 
who took the treatment, 225 (86.8%) cases were cured or 
completed treatment.
No relationship was found between the final case status 
and the place of treatment (P . 0.05) or treatment regimen 
followed (P . 0.05).
Among the 253 patients who were successfully treated, 5 
(1.9%) were rediagnosed with active TB in the observation 
period (1996–2006), one of them twice and another who had 
not completed the DOTS. The time of recurrence ranged 
between 1 and 6 years. There was no statistically significant 
relationship found between new cases TB or retreated TB 
and final status (P . 0.05).
Discussion
The foremost strategy of the WHO to achieve TB control is 
to apply DOTS to every single TB patient.13 As this recom-
mendation addresses mainly the poorest countries of the 
world, every country needs to adapt this WHO proposal to 
its own social, epidemiologic, and economic situation.
In our health area, 259 DOTS, according to the criteria set 
out in GPPCT, were conducted by the UTB during the years 
of this study, representing 10.5% of all registered cases. 
Table 2 DOTS treatment locations
Place of treatment N° DOTS %
UTB 97 37.5
Health center 72 27.8
Social services 42 16.2
Family 31 12
Drugs unit 13 5
School 3 1.2
Hospital 1 0.4
Abbreviation: DOTS, directly observed therapy, short course; UTB, tuberculosis 
unit at Santiago de Compostela University Hospital, Spain.
Table 1 Distribution of DOTS TB cases in Santiago de Compostela by year and type of tuberculosis
Year New TB cases 
Nº/% DOTS
Retreatment cases Total 
Nª/% DOTS/%
Treatment after default 
Nº/% DOTS
Relapse 
N/% DOTS
Chronic 
Nº/% DOTS
1996–2000 1263/90.6 
94
29/2.1 
26
98/7 
24
4/0.3 
4
1394/56.8 
148 
2001–2006 997/93.9 
85
7/0.7 
5
58/5.4 
21
0 
0
1062/43.2 
111
Total 2260/92 
179
36/1.5 
31
156/6.4 
45
4/0.2 
4
2456/100 
259/10.5
Abbreviations: DOTS, directly observed therapy, short course; TB, tuberculosis; N, number of cases.Risk Management and Healthcare Policy 2010:3 submit your manuscript | www.dovepress.com
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Treatment supervision was achieved in all of the diagnosed 
chronic patients as well as in all the MDR-TB cases. Among 
the patients treated after default, DOTS was performed in 
86.1% of the cases. Supervision was carried out in 28.8% 
of the relapsed cases and in 7.9% of the new TB cases. The 
low percentage among relapsed cases could be explained by 
the majority of these patients having a very old TB episode 
(more than 15 years prior). The analysis of the results shows 
a statistically significant (P , 0.05) decrease in the number 
of treatments after default relapse and the elimination of 
chronic cases in the last 6 years of the studied period.
The most recent WHO report shows that DOTS has a very 
different distribution throughout Europe, ranging from 0% to 
100% (67% average). The statistics in this report emphasize 
that Western European countries, with low TB incidence, do 
not use the DOTS strategy.1
The patient profile described in the WHO report is very 
similar to the one shown in our patients where most were 
male and the average age was 39.9 years. This is consistent 
with the classical studies performed on populations in high 
TB incidence areas, which show men are in the majority 
and that there is a bimodal curve with a first high peak for 
young patients.14
Cases of pulmonary TB cases probably take priority 
when a TB control program is conducted because of their 
potential to infect others if left untreated.15 In our study, 
87.6% of the cases undergoing DOTS presented with pul-
monary TB. Cavitated forms in chest radiology were shown 
in 46.7% of patients, 74.9% of whom had a positive AFB 
result on diagnosis. From positive AFB smears, the TB 
Table 3 Patterns and treatment regimen for tuberculosis
Standard treatment Treatment after
Regimen New Default Relapsed Chronic
2HRZ + 4HR Daily 85 8 4 –
  Twice/week 2 1 – –
2HRZE + 4HR Daily 32 10 16 –
  Twice/week 3 – – –
2Rbhz + 4RbH Daily – 1 – –
2HRE + 7RH Daily 8 1 1 –
2HRZES + 1HRES + 5HRE Daily 5 – 8 –
Prolonged stándard treatment        
2HRZ + 10 HR Daily 2 1 – –
2HRZ + 7HR Daily 4 2 1 –
2HRZE + 10HR Daily 8 1 1 –
2HRZE + 7HR Daily 1 1 – –
2HRE + 10HR Daily 7 2 2 –
2HRSZ + 10HR Daily – – 2 –
Other treatments          
Resistant TB/multiresistant or  
intolerances
 
2HRZE + 10RE Daily 2 1 1 –
2HRZ + 10RE Daily 4 – – –
2HZE + 16HE Daily 1 – – –
2REZS + 10RE Daily – – 1 –
Treatment with first-line drugs + quinolones Daily 8 1 2 –
Treatment with first-line drugs +  
quinolones + other second line drugs
Daily 5 1 6 3
Other treatments with first- and  
second-line drugs
Daily 2 – – 1
Abbreviations: TB, tuberculosis; H, isoniazid; R, rifampicin; E, ethambutol; Z, pyrazinamide; S, streptomycin; Rb, rifabutin.
Table 4 Final status of tuberculosis cases after DOTS
Final status of the case New 
TB/%
Retreatment 
TB/%
Total/%
Bacteriological cure  7/3.9 5/6.2 12/4.6
Treatment completed  151/84.4 62/77.5 213/82.2
Defaulted 8/4.5 2/2.5 10/4
Death from TB  0 2/2.5 2/0.8
Death from other causes 6/3.4 5/6.3 11/4.2
Transferred out 7/3.8 4/5 11/4.2
Total 179/69.1 80/30.8 259
Abbreviations: DOTS, directly observed therapy, short course; TB, tuberculosis.Risk Management and Healthcare Policy 2010:3 submit your manuscript | www.dovepress.com
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rate was 27.1 cases/100,000 people in 1996 which fell to 
9.2 cases/100,000 people in 2006. Despite this reduction, 
the rates are higher than expected if we consider the social 
and economic status of our area, and, more alarmingly, too 
high when compared to the rates in other Western European 
countries such as Germany (6.5 cases/100,000 people) or the 
United Kingdom (14 cases/100,000 people). Fortunately the 
figures are lower than the ones in Eastern European countries 
such as Russia (106.3 cases/100,000 people) or Georgia 
(143.1 cases/100,000 people).16
HIV infection has a high impact on TB epidemiology 
in Spain because our country has the highest incidence of 
HIV-TB coinfection in Europe.17 However, in Galicia, from 
the very beginning of the GPPCT, it has been demonstrated 
that TB continues to show a classical epidemiologic distri-
bution, without the influence of HIV .6 The statistics reveal 
a coinfection rate of about 4.3% in 1996 and 3.3% in 2006. 
In none of the years of the study was this coinfection rate 
higher than 10%.
Since the development the GPPCT, the UTB has over-
come serious problems in order to instigate DOTS, particu-
larly in the very early days. Implementing DOTS is difficult. 
In addition to this, population dispersion around the health 
area makes it even more complicated to provide treatment 
to patients.
WHO firstly recommends the use of internationally 
accepted guidelines for TB treatment. This universally stan-
dard treatment (2RHZ + 4RH, 2RHZE + 4RH)) was used in 
71.4% patients who newly presented with TB without com-
plications in their illness. WHO endorses 6-month regimens 
based on rifampicin, isoniazid, and pirazinamide in areas 
where primary resistance to isoniazid is lower than 4%.18 
This resistance rate has never been exceeded in our study and, 
more importantly, primary resistance reached only 2.9%.19,20 
Second-line drugs such as capreomycin and prothionamide 
were the drugs selected for 11.1% patients who developed 
resistance and/or drug intolerance. The DOTS strategy is 
critical for this kind of drug management; 90.3% of the cases 
after default received standard treatments, while the percent-
age decreased to 77.8% in relapse cases. Drug regimens for 
chronic patients were individualized according to their anti-
biograms results and their history of previous drug use.
Quinolone use in TB treatment is now a controversial topic. 
Ten percent of the patients from our study received quinolo-
nes. Ciprofloxacin was the option used at the very beginning 
of the study time period, but it was replaced by levofloxacin 
in recent years. This third generation quinolone, as well as 
moxifloxacin (fourth generation drug), are both reported to be 
better treatment options for complicated TB cases.21,22 A recent 
study showed that the use of moxifloxacin was associated with 
culture conversion and the authors suggest that moxifloxacin, in 
combination with other first-line anti-TB drugs, could shorten 
the time needed to cure TB by several months.23
Most patients in our study had a once-daily regimen 
and only 2.3% received an intermittent drug administration 
schedule. Intermittent regimens have shown to be as effective 
as the ones based on once-daily administration and are, as 
well, the less costly option.24 Studies have also shown that 
intermittent regimens do not increase the rate of TB drug 
resistance.25 Now that some of these infrastructure problems 
have been solved, it would be very interesting to implement 
this kind of regimen.
In our health area, social and familial problems are the 
major inclusion criteria in DOTS programs. Drug use and 
alcoholism, for instance, can lead to inadequate compliance 
in drug therapy. It should be noted that the retreated group 
had a statistically significant multifactor risk.
Few studies carried out under routine program condi-
tions have reported disease recurrence. Published values 
range from 0% to 14%.26 TB recurrence is a useful indica-
tor of treatment efficacy under the DOTS strategy. In our 
series, recurrence under DOTS was low (1.9%), indicating 
the efficacy of the treatment. DOTS results were potentially 
unsatisfactory in 13.1% of patients. Even so, we think this 
is a good result given the historical difficulty in achieving 
drug compliance in many TB patients.
Recently, new and original DOTS systems have been devel-
oped. In the Valencian Region of Spain, a pilot program based 
on DOTS administration by pharmaceutical chemists has begun. 
First results show that it is good alternative for the future.27
The introduction of the DOTS strategy under the GPPCT, 
together with strict control and follow-up of all TB diagno-
ses in our health area, has combined to reduce the illness 
incidence rate of TB, which ranged from 72.7 cases/100,000 
people in 1996 to 27.1 cases/100,000 people in 2006. Even so, 
we are far from achieving total TB control. A re-evaluation 
of the situation is needed, as is a deep analysis of the causes 
of the delay in diagnosis, which naturally leads to a delay in 
the start drug therapy.28 Decisions on new approaches to the 
problem should be made according the DOTS strategies.
Conclusions
Patient selection criteria for DOTS administration were 
very important for TB control in our region. The group of 
retreated patients often had more than one risk factor for 
inclusion in DOTS (P , 0.01). Standard treatment guidelines Risk Management and Healthcare Policy
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recommended by WHO were used in 71.4% patients, 87.1% 
of whom achieved a satisfactory final status. The level of TB 
recurrence in patients under the DOTS strategy was low.
Although it is not possible to determine the exact influ-
ence of the DOTS strategy, its introduction under the condi-
tions set up by the GPPCT has helped to improve the control 
of TB in our health area.
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